Navigation Links
Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
Date:4/28/2010

LAKE ZURICH, Ill., April 28 /PRNewswire/ -- Fenwal, Inc. (www.fenwalinc.com), a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.  

The Fenwal Amicus® separator is an advanced medical device used to collect platelets and other blood components from donors.  The addition of wireless data management allows blood centers to easily access procedure information to monitor machine and operator performance without the added cost or capital investment of rewiring facilities.

During customer trials, blood centers reported that the Amicus® separator with DXT helped them increase platelet yield per donor by enabling better analysis of performance by device, operator and collection site.  

Amicus® separators with DXT offer blood-center professionals easy-to-read, on-demand reports concerning donations at multiple locations.  These reports help identify opportunities for improvement and training.

"With Amicus® DXT from Fenwal we increased our platelet split rate 23 percentage points," said Karen Nielsen, M.B.A., MT(ASCP)SBB, blood services group manager of ARUP Blood Services, one of the largest blood collectors in Utah. "The technology and data-analysis reports have helped our staff measure and improve our performance and productivity and helped to assure platelets are available for critical therapies." By collecting and splitting a large platelet product from eligible donors, blood centers can obtain two or more therapeutic doses from a single platelet donation. 

Fenwal DXT technology features open-source compatibility, enabling connection to virtually any blood-center information system.  It can also generate reports using proprietary templates offered by Fenwal, or via commercially available tools such as Crystal Reports.  Fenwal plans to add wireless functionality to its other automated blood collection and separation systems.

"Fenwal's data management strategy is designed to deliver what blood centers say they want most—a simple, open-ended solution that allows them to securely capture and analyze procedure data from different locations without having to make a big investment in multiple systems and training," said William H. Cork, Fenwal chief technology officer and senior vice president.  "Blood centers, like many other companies, want to automate data collection to optimize operations, address training needs and improve documentation.  We are pleased to introduce this customer-focused innovation for use with our popular Amicus® separator."

The Amicus® separator with DXT uses barcode scanners to capture kit lot numbers, operator ID and donation ID for each collection procedure.  The information is then sent through a secure wireless connection from the Amicus® separator to a server connected through the blood center's network.  Standard reports analyze procedure data by operator and by device, with data typically available within minutes of a completed procedure.  

Amicus® separator with DXT is one of several recent advancements for the Amicus® separator.  Earlier this year, Fenwal received FDA clearance to market the Amicus® separator for collecting platelets stored in Fenwal InterSol® platelet additive solution, the first and only platelet additive solution available in the United States.  

Blood centers interested in learning more about the Amicus® separator with DXT and InterSol® platelet additive solution, should contact their Fenwal account executive or call 1-800-3FENWAL (1-800-333-6925) in the United States.

About Fenwal

Fenwal, Inc. is a global medical technology company focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components.  Fenwal is unique in the depth of its experience and commitment to transfusion medicine.  The company offers the broadest range of products for the automated and manual collection of blood and blood components.  Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories.  Fenwal developed the first flexible, single-use container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components.  Today, the company's products and advanced collection and separation technologies are used to help treat patients on six continents.  Fenwal, Inc. is based in Lake Zurich, Illinois.  For more information, please visit www.fenwalinc.com.


'/>"/>
SOURCE Fenwal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
2. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
3. Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets
4. William Cork Joins Fenwal as Chief Technology Officer
5. Mylan Receives Approval for Generic Version of Flomax(R)
6. BioMedix Receives Clinical Approval for TRAKnet Software
7. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
8. Flexuspine Receives FDA Conditional Approval to Begin a Feasibility Study of Its FSU (Functional Spinal Unit) Total Spine Arthroplasty System in the United States
9. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
10. ATS Medical Receives Approval to Commercialize the ATS Simulus Annuloplasty Products in Canada
11. Actavis Receives Approval of Alprazolam ODT in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):